Desalting and Buffer Exchange Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Desalting and Buffer Exchange Market is projected to experience significant growth, rising from USD 1.24 billion in 2025 to USD 2.33 billion by 2031, with a Compound Annual Growth Rate (CAGR) of 11.01%. These essential chromatographic techniques are utilized to separate soluble macromolecules from smaller impurities or to adjust the buffer composition of biological samples for downstream compatibility.

The market is largely driven by the vigorous expansion of the biopharmaceutical sector, where the manufacturing of monoclonal antibodies and recombinant proteins demands high-purity isolation. This growth is supported by massive industry investment; for instance, the European Federation of Pharmaceutical Industries and Associations reported that the research-based pharmaceutical industry invested approximately €55.00 billion in R&D across Europe in 2024. Furthermore, the growing emphasis on proteomics and genomics research requires precise sample preparation, further stimulating the demand for these purification technologies.

However, the market faces a substantial obstacle due to the high operational costs and technical complexities associated with advanced chromatography systems. These financial and technical hurdles often restrict access for smaller laboratories and academic institutions with limited budgets, thereby decelerating the universal adoption of automated solutions. Consequently, despite the clear necessity for high-quality biomolecule separation, the significant capital expenditure required for specialized desalting instrumentation continues to pose a challenge to broader market expansion.

Market Drivers

The growth of Contract Development and Manufacturing Organization (CDMO) services acts as a primary catalyst for the adoption of desalting and buffer exchange technologies. As biopharmaceutical companies increasingly outsource production to optimize costs and access specialized expertise, CDMOs are scaling their facilities to manage larger volumes of biologics, which creates a need for robust downstream processing capabilities for contaminant removal and buffer modification.

This operational scaling drives significant investment in purification infrastructure to ensure seamless workflow integration. For example, Lonza’s 'Annual Report 2024', released in January 2025, indicates the company invested CHF 1.4 billion in capital expenditure throughout 2024, with approximately 60% deployed for growth projects including large-scale biologics plants. Such substantial capital allocation by major CDMOs underscores the critical need for advanced processing equipment to support the growing global manufacturing footprint.

Simultaneously, the increasing demand for monoclonal antibodies (mAbs) is directly expanding the market, as these complex molecules require precise buffer exchange steps to ensure stability and prevent aggregation during formulation. The dominance of mAbs in the drug pipeline drives the requirement for high-throughput desalting solutions that can maintain strict purity standards while accommodating accelerated development timelines.

This momentum is evident in recent regulatory outcomes; according to Drug Discovery and Development in December 2024, the article '4 trends in FDA novel approvals in 2024' noted that the FDA approved 13 monoclonal antibodies in 2024, marking the highest annual count for this modality since 2015. This high approval rate reflects a broader surge in therapeutic innovation and financial backing for life sciences, which further fuels the market. According to the BioIndustry Association in January 2025, the UK biotech sector secured £3.5 billion in investment during 2024, indicating the sustained capital flow that supports the continued development and purification needs of these antibody-based therapies.

Market Challenges

The substantial capital expenditure and operational costs associated with advanced chromatography systems present a significant barrier to the growth of the Global Desalting and Buffer Exchange Market. While large biopharmaceutical companies may possess the resources to absorb these expenses, smaller laboratories, academic institutions, and early-stage biotech startups often face restrictive budgets that prevent the acquisition of automated desalting instrumentation. These advanced systems are essential for high-throughput and precise buffer exchange; however, the financial burden forces many budget-constrained facilities to rely on manual, time-consuming, and less consistent methods, thereby limiting the broader adoption of automated technologies.

This financial strain is exacerbated by tightening funding environments for smaller innovators who rely heavily on non-dilutive capital to upgrade their infrastructure. According to the BioIndustry Association, in 2024, grant funding available to the biotech sector declined to £33 million, with a 30% drop in the average grant size compared to the previous period. Such a reduction in available capital directly hampers the purchasing power of smaller market participants, effectively stalling the universal transition from manual techniques to the sophisticated automated solutions that drive market revenue.

Market Trends

The adoption of automated liquid handling workflows is fundamentally reshaping the Global Desalting and Buffer Exchange Market by addressing the critical bottleneck of manual sample processing. Laboratories are increasingly transitioning to robotic workstations that ensure high reproducibility and throughput, effectively mitigating the risks of human error associated with traditional manual desalting methods. This technological integration is particularly vital for handling large sample libraries in genomics and proteomics, where consistency is paramount. The robust market demand for these automated solutions is evident in the financial performance of key enablers; according to Tecan Group’s 'Annual Report 2023' from March 2024, the company reported full-year sales of CHF 1.07 billion, reflecting the sustained industry investment in advanced laboratory automation infrastructure.

Concurrently, a sharpened focus on sustainable and eco-friendly buffer solutions is driving the development of purification technologies that minimize environmental impact. As the volume of biopharmaceutical production rises, the industry is actively seeking to reduce the massive water and chemical footprint associated with buffer preparation and exchange processes. This push toward green chromatography is prompting manufacturers to optimize solvent consumption and implement rigorous waste reduction strategies. This commitment is quantifiable among major industry leaders; according to Merck KGaA’s 'Sustainability Report 2023' released in April 2024, the company achieved a 5% reduction in its key Waste Score ahead of schedule, underscoring the sector-wide imperative to adopt more efficient and environmentally responsible purification workflows.

Key Players Profiled in the Desalting and Buffer Exchange Market

• Thermo Fisher Scientific Inc.
• Avantor Inc.
• Bio-Rad Laboratories Inc.
• Merck KGaA
• Danaher Corporation
• Repligen Corporation
• Agilent Technologies Inc.
• Biotage AB
• Norgen Biotek Corp
• Sartorius AG

Report Scope

In this report, the Global Desalting and Buffer Exchange Market has been segmented into the following categories:

Desalting and Buffer Exchange Market, by Technique:

• Filtration
• Chromatography
• Precipitation

Desalting and Buffer Exchange Market, by Product:

• Kit
• Cassettes & Cartridges
• Filter Plates
• Spin Columns
• Membrane Filters
• Other Consumables
• Accessories

Desalting and Buffer Exchange Market, by Application:

• Bioprocess Applications
• Pharmaceutical and Biotechnology Companies
• CMOS & CROS
• Academic & Research Institutes
• Diagnostic Applications

Desalting and Buffer Exchange Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Desalting and Buffer Exchange Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.